Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022

Amgen is presented as a defensive healthcare holding for a potential market downturn, supported by historical relative resilience during the 2008 financial crisis and the 2022 bear market. Q2 revenue rose 10% year over year to $10.1 billion, with 22 products delivering double-digit sales growth, despite denosumab—nearly 20% of 2024 revenue—losing U.S. and European patent exclusivity. The company offers a 2.6% dividend yield versus the S&P 500's 1.1%, although pipeline risk remains after Novartis' pelacarsen failure drove Amgen shares down about 10% in one day due to read-through concerns for olpasiran.

Analysis

AMGN's defensive appeal is real, but the relevant question is not beta in prior drawdowns; it is whether investors are being compensated for a more levered, post-acquisition earnings profile while a major franchise faces biosimilar erosion. Revenue diversification can cushion the headline decline, but it does not eliminate gross-margin dilution, commercial spend, and working-capital drag as replacement products scale. In a risk-off tape, the stock can outperform cyclicals; over 6-18 months, valuation support depends on converting growth products into enough free cash flow to protect dividend growth and deleveraging.

The more actionable near-term catalyst is clinical read-through rather than macro defensiveness. NVS's Lp(a) outcome raises the probability that the biology, endpoint selection, or treatment timing is more difficult than the market had assumed; olpasiran therefore carries a wider downside distribution than a simple competitor failure implies. A favorable AMGN outcome could create substantial pipeline optionality, while a disappointing result would likely trigger both asset-value markdowns and a reassessment of the company's ability to offset mature-product pressure.

Consensus may overstate the benefit of obesity optionality. MariTide must demonstrate not only durable weight loss but an acceptable tolerability/discontinuation profile and competitive positioning against increasingly potent oral and injectable offerings from LLY and NVO. That makes AMGN better viewed as a lower-beta large-cap pharma holding with event risk, not a pure defensive compounder; the dividend alone is unlikely to prevent multiple compression if pipeline confidence weakens.

Key Decisions for Investors

• Use AMGN as a tactical defensive overweight versus SPY or XLI over the next 1-3 months only if macro volatility rises; target relative outperformance rather than absolute upside. Exit the hedge if AMGN underperforms SPY by 5% after a broad risk-off move, which would signal company-specific concerns are overwhelming defensiveness.
• Do not add aggressively ahead of olpasiran data without updated details on endpoint design, population, and expected timing. Set an event watch: a clear efficacy/safety validation supports a 6-12 month long; evidence that the class has limited cardiovascular outcome utility would falsify the pipeline-offset thesis.
• For biotech event exposure, prefer a defined-risk structure: buy AMGN call spreads dated beyond the expected olpasiran catalyst and fund selectively with higher-strike calls, rather than owning uncapped downside around clinical uncertainty. Size only after implied volatility and catalyst timing are verified.
• Monitor quarterly free cash flow, net-debt reduction, denosumab erosion, and dividend-growth guidance. A material cut to dividend-growth expectations or failure of newer products to offset erosion for two consecutive quarters would remove the principal defensive-support argument.